| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Twenty two eyes of eleven cases with retinopathy of prematurity (ROP) were treated by intravitreal ranidizmab injection (IVR). Average post-conceptual age at birth was 23.9 weeks and average birth weight was 653 gr. Sixteen eyes (73%) have aggressive posterior ROP (APROP) or zone I ROP, and six eyes (27%) have zone II ROP. Average gestational age at IVR was 32.6 weeks. Temporal regression and reactivation were seen on all of eyesAdditional treatment required on eight eyes (50%) with APROP or zone I ROP.
The results were compared with thirty four eyes of seventeen eyes treated by intra vitreal bevasizumab injection (IVB). No significant difference was observed between IVR treated eyes and IVB treated eyes on post-conceptual age at birth, birth weight, gestational age at initial treatment, temporal regression rate, reactivation rate, additional treatment rate and final outcome. Plasma VEGF concentration reduced at one week after IVR, and tended to recover at two weeks following IVR.
|
